Clinical Trials
13 trialsNCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
NCT02282917 2025-12-05
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
Phase EARLY_PHASE1 Terminated
NCT03095248 2025-04-22
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Phase 2 Terminated
NCT03710564 2023-01-30
MERLIN
Novartis
Phase 3 Terminated
NCT02831257 2022-06-13
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Phase 2 Completed
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT01767792 2021-02-12
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
University of Alabama at Birmingham
Phase 2 Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT00863122 2021-01-12
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT01207687 2018-08-27
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
National Cancer Institute (NCI)
Phase 2 Completed
NCT01419639 2017-07-18
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Phase 2 Completed
NCT00973739 2016-03-22
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed